Since then TPIV raised about $10m cash and and confirmed that the drug is active.TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients.The potential to treat ~85% of breast cancer patients with this HER2/neu therapeutic approach is significant. The successful completion of this HER2/neu vaccine Phase I study and the robust immune responses detected provides TapImmune with a second Phase II clinical candidate and an expanded clinical pipeline for the treatment of breast and ovarian cancer. It also further validates the technology and the approach developed at Mayo Clinic by Professor Keith Knutson."
And Per last update 06/19/15 "we plan to progress them into
Phase II clinical trials in 2015"
TPIV can not be compared with JUNO. cap is $5.5B,64m net loses,Accumulated deficit more than 400m , TPIV cap is 30m now,almost zero debt, 10-14m in cash. this could make a 7-10 times investment return before an uplisting to the NASDAQ (chech the pr below)
The Company has a deep pipeline of potential blockbuster immunotherapies under development. Two of the clinical programs are completing Phase I studies and are expected to advance to Phase II in 2015. These are major inflection and valuation events, and we believe that, in light of these assets, the Company is significantly undervalued. Over the past year a number of highly visible transactions and billion dollar acquisitions have taken place that validate the work we are doing. We believe that, if our treatment successfully reaches commercialization, our treatment is applicable to 50% of the HER2/neu Breast Cancer market, which is a $21 billion annual market. We further believe that if our Ovarian Cancer treatment reaches commercialization, it will be applicable to 95% of the market which Decision Resources, one of the world's leading research firms for pharmaceuticals and healthcare, believes will triple in the next 10 years to at least $1.5 billion annually
In addition, we will continue to work on deficit reduction and capital improvement in order to make the required benchmarks for an uplisting to the NASDAQ. To that end we are also anticipating the result of grant applications submitted early this year.
As mentioned before,TPIV wants publicity and to get off the bulletin board and onto the Nasdaq,it's obvious.
TPIV is the only OTC stock Dart(6.6 Billionaire) has ever partnered with. Kenneth Dart/Eastern Capital was holding only NASDAQ stocks before he grabbed a solid positing here. and proved he is buying more and more like he did just 2 weeks ago.
He owns 23million shares of VCEL, Vericel Corp. as well.
Owns 2million VSTM since Jan, 2015.
Owns 22million shares IBIO.
Owns 8million shares PPHM.
The stock is very undervalued at this point, when Edith Perez who worked on the Herceptin trials for Roche, came out and said that now she believes they may be a vaccine for TNBC, not too mention HER2/nue, Ovarian and possibly many others.
DART"S participation seems to have solidified their path to getting up-listed as soon as possible, reducing the warrant prices has simply [as GLYNN has stated] expedited that process.
They have in the past month's put together all the pieces to make the up-listing possible by year end [possibly sooner], the stock should never will be as low as it now again, and I believe that there will be a fast retraction in the share price moving forward.
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
